Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > ARCHIVE
ARCHIVE
- Ten More Items to Be Allowed to Be Advertised by Medical Facilities
January 1, 2001
- BUSINESS NEWS IN BRIEF
January 1, 2001
- Tsuruha Acquires Drug Tomato in Iwate
January 1, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
January 1, 2001
- Kaletra Included in NHI List
January 1, 2001
- Fukuda Denshi to Charge Customers for Maintenance Services
January 1, 2001
- Welfide Licenses Glaucoma Treatment to Senju
January 1, 2001
- NHI Price Listing of Relenza, Tamiflu No Sooner Than Mid February
January 1, 2001
- OTC NEWS IN BRIEF
January 1, 2001
- New Year's Greeting
January 1, 2001
- Ministries, Agencies to Be Reorganized
January 1, 2001
- Many Know about Anti-smoking Aids, But They Are Not Commonly Used: Survey
January 1, 2001
- The Year 2000 in RetrospectJapanese Drug Industry at the Mercy of Large Waves of Globalization
January 1, 2001
- CST Report Urges Strengthening Lifestyle-related Disease Research
January 1, 2001
- Hitachi to Provide High Tech Healthcare Services
January 1, 2001
- 'New Opportunities and New Solutions Are within Reach'
January 1, 2001
- REGULATORY NEWS IN BRIEF
January 1, 2001
- Siemens-Asahi Medical to Launch New Maintenance-free Spiral CT
January 1, 2001
- PhRMA Japan Representative Moves to Kamiyacho
January 1, 2001
- Kraft: Consolidated Half-year Sales Mark ¥13.5 Bil.
January 1, 2001
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…